Department of Pathology & Clinical Labs, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran 1416634793, Iran.
Int J Mol Sci. 2024 May 7;25(10):5069. doi: 10.3390/ijms25105069.
Pancreatic ductal adenocarcinoma (PDAC) is poised to become the second leading cause of cancer-related death by 2030, necessitating innovative therapeutic strategies. Genetic and epigenetic alterations, including those involving the COMPASS-like complex genes, have emerged as critical drivers of PDAC progression. This review explores the genetic and epigenetic landscape of PDAC, focusing on the role of the COMPASS-like complex in regulating chromatin accessibility and gene expression. Specifically, we delve into the functions of key components such as , , , , and , highlighting their significance as potential therapeutic targets. Furthermore, we discuss the implications of these findings for developing novel treatment modalities for PDAC.
胰腺导管腺癌 (PDAC) 有望成为 2030 年癌症相关死亡的第二大主要原因，这需要创新的治疗策略。包括涉及 COMPASS 样复合物基因在内的遗传和表观遗传改变已成为 PDAC 进展的关键驱动因素。本综述探讨了 PDAC 的遗传和表观遗传景观，重点关注 COMPASS 样复合物在调节染色质可及性和基因表达中的作用。具体而言，我们深入研究了关键成分（如 、 、 、 和 ）的功能，强调它们作为潜在治疗靶点的重要性。此外，我们还讨论了这些发现对开发 PDAC 新型治疗方法的意义。
Zotero 插件
